<DOC>
	<DOC>NCT00057720</DOC>
	<brief_summary>The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.</brief_summary>
	<brief_title>TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criteria include: Considered platinum refractory or resistant according to standard criteria Progressed during or following completion of one secondline treatment with Doxil/Caelyx or Hycamtin Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer Measurable disease according to RECIST criteria with documented tumor progression Exclusion criteria include: Treatment with secondline chemotherapy other than Doxil/Caelyx or Hycamtin History of whole pelvis radiation therapy within 12 months of enrollment Clinically significant cardiac disease Evidence of gross hematuria at the time of study entry Any signs of intestinal obstruction interfering with nutrition at the time of study entry Pregnant or lactating women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>ovary</keyword>
</DOC>